Results 151 to 160 of about 1,866 (169)

Bimekizumab

Reactions Weekly, 2022
openaire   +1 more source

Bimekizumab Versus Ustekinumab for the Treatment of Moderate to Severe Plaque Psoriasis (BE VIVID): Efficacy and Safety From a 52-Week, Multicentre, Double-Blind, Active Comparator and Placebo Controlled Phase 3 Trial

Lancet, The, 2021
Kristian Reich, Kim A. Papp
exaly  

Bimekizumab in Patients With Active Psoriatic Arthritis and Previous Inadequate Response or Intolerance to Tumour Necrosis Factor-α Inhibitors: A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial (BE COMPLETE)

Lancet, The, 2023
Deepak Assudani, Vishvesh Shende, Jason Coarse   +2 more
exaly  

Bimekizumab in Patients With Active Psoriatic Arthritis: Results From a 48-Week, Randomised, Double-Blind, Placebo-Controlled, Dose-Ranging Phase 2b Trial

Lancet, The, 2020
Joseph Frank Merola, Arthur Kavanaugh, Georg Schett   +2 more
exaly  

Bimekizumab-bkzx

Clinical Therapeutics
openaire   +2 more sources

Bimekizumab for Patients With Moderate to Severe Plaque Psoriasis: 60-Week Results From BE ABLE 2, a Randomized, Double-Blinded, Placebo-Controlled, Phase 2b Extension Study

Journal of the American Academy of Dermatology, 2020
Christopher Griffiths, Joseph Frank Merola, Kim A. Papp   +2 more
exaly  

Bimekizumab effective across the axSpA spectrum

Nature Reviews Rheumatology, 2023
openaire   +2 more sources

First-in-Human Randomized Study of Bimekizumab, a Humanized Monoclonal Antibody and Selective Dual Inhibitor of IL-17A and IL-17F, in Mild Psoriasis

British Journal of Clinical Pharmacology, 2017
Sophie Glatt, Birgit Haier
exaly  

Bimekizumab safe and effective for psoriatic arthritis

Nature Reviews Rheumatology, 2023
openaire   +2 more sources

Bimekizumab Effective on Skin and Joints

International Journal of Dermatology
Thomas Herzinger, Sonja C. Molin
openaire   +2 more sources